Featuring a slide presentation and related discussion from Dr Marwan Fakih, including the following topics:

• Overview of etiology, incidence and staging of squamous cell cancer of the anal canal (SCAC) (0:00)
• Systemic therapy approaches to the management of recurrent unresectable and metastatic SCAC (6:17)
• Available data with anti-PD-1 (pembrolizumab, nivolumab, retifanlimab) and anti-CTLA-4 (ipilimumab) agents in the management of unresectable metastatic SCAC previously treated with chemotherapy (12:59)
• Immunotherapy combined with chemotherapy for the front-line treatment of SCAC (20:48)
• Efficacy and safety of retifanlimab combined with carboplatin/paclitaxel as first-line treatment for SCAC in the Phase III POD1UM-303 trial (23:43)

CME information and select publications

Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics:

• EMBARK trial: Enzalutamide for biochemically recurrent prostate cancer (0:00)
• Final results from the Phase III PRESTO study: Combined androgen blockade for high-risk biochemically relapsed prostate cancer (4:05)
• Other novel treatment strategies for patients with metastatic prostate cancer (10:31)

CME information and select publications

Featuring an interview with Dr Kathleen N Moore, including the following topics:

• Overview of the mechanism of action and pharmacology of antibody-drug conjugates (ADCs) (0:00)
• Comparing toxicities of conventional chemotherapy and ADCs (6:26)
• Potential of ADCs as maintenance therapy for ovarian cancer (11:35)
• Treatment based on platinum sensitivity and homologous recombination-deficiency status (15:10)
• Case: A woman in her mid 70s presenting with Stage IV ovarian cancer receives raludotatug deruxtecan (18:46)
• Case: A woman in her mid 60s with relapsed/refractory ovarian cancer receives mirvetuximab soravtansine (41:22)
• Case: A woman in her early 70s with relapsed/refractory ovarian cancer receives multiple ADCs in clinical trials (45:57)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Kathleen N Moore, including the following topics:

• Overview of developments and opportunities with antibody-drug conjugates (ADCs) in ovarian cancer(0:00)
• Targeting folate receptor alpha with mirvetuximab soravtansine (3:59)
• Targeting TROP2 with ADCs (9:12)
• Targeting folate receptor alpha with ADCs (14:17)
• Targeting cadherin-6 with ADCs (17:27)
• Targeting HER2 with ADCs (26:12)
• Potential of ADCs in the treatment of platinum-sensitive ovarian cancer (28:38)

CME information and select publications

Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics:

• Introduction (0:00)
• Neoadjuvant Treatment for Localized Colorectal Cancer (CRC) — Dr Seligmann (2:39)
• Emerging Novel Approaches to Adjuvant Treatment for Localized CRC — Dr Lieu (33:18)
• Role of Circulating Tumor DNA Testing in Localized CRC — Dr Cohen (59:43)

CME information and select publications

Featuring perspectives from Dr Hanny Al-Samkari, Dr Cindy Neunert and Prof Francesco Zaja, including the following topics:

• Introduction (0:00)
• Case: A woman in her early 30s with chronic relapsing immune thrombocytopenia (ITP) receives eltrombopag with ongoing stabilization of platelet counts — Neil Morganstein, MD (2:03)
• Case: A woman in her late 60s with a long history of ITP controlled by eltrombopag experiences acute exacerbations — Bhavana (Tina) Bhatnagar, DO (6:42)
• Clinical Manifestations and Initial Management of ITP — Dr Neunert (18:07)
• Case: A woman in her early 80s with metastatic adenocarcinoma of the lung who responded to carboplatin/pemetrexed/pembrolizumab presents with ITP after 14 months of maintenance pembrolizumab — Susmitha Apuri, MD (33:14)
• Incorporation of Thrombopoietin Receptor Agonists and Other Second-Line Therapies into ITP Management — Prof Zaja (40:19)
• Case: A woman in her late 60s with stress cardiomyopathy and corticosteroid-refractory ITP receives rituximab followed by eltrombopag — Eric Fox, DO (1:00:44)
• Current and Future Role of Novel Therapies in ITP — Dr Al-Samkari (1:03:47)

CME information and select publications

Featuring an interview with Dr Terence Friedlander, including the following topics:

• Final analysis of the Phase III, open-label, randomized POTOMAC trial (0:00)
• KEYNOTE-905 trial: Perioperative enfortumab vedotin with pembrolizumab for muscle-invasive bladder cancer (MIBC) (5:25)
• The neoadjuvant gemcitabine intravesical system TAR-200 for patients with MIBC: Primary analysis of the SunRISe-4 trial (14:07)
• Circulating tumor DNA-guided therapies for MIBC (18:41)

CME information and select publications

Featuring an interview with Dr Sagar Lonial, including the following topics:

• KLN-1010: A novel, in vivo gene therapy generating anti-BCMA chimeric antigen receptor T cells (0:00)
• Phase III DREAMM-7 and DREAMM-8 studies of belantamab mafodotin-based combination therapy for patients with relapsed/refractory (R/R) multiple myeloma (MM) (5:37)
• Effectiveness of ciltacabtagene autoleucel for patients with R/R MM (11:04)
• Low-dose tocilizumab for mitigation of the cytokine release syndrome associated with bispecific antibodies (16:04)
• Talquetamab with teclistamab for patients with R/R MM in Phase Ib of the RedirecTT-1 trial (19:24)

CME information and select publications

Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics:

• Introduction (0:00)
• HER2-Targeted Approaches for Advanced Gastroesophageal Cancers — Dr Ajani (2:02)
• Faculty Panel Discussion: Cases and Questions from the Community (14:13)
• Targeting Claudin 18.2 in Advanced Gastroesophageal Cancers — Dr Strickler (37:29)
• Faculty Panel Discussion: Cases and Questions from the Community (49:21)
• Optimal Incorporation of Immunotherapeutic Strategies into Treatment for Patients with Metastatic Gastroesophageal Tumors — Dr Mehta (1:09:56)
• Faculty Panel Discussion: Cases and Questions from the Community (1:22:02)
• Other Novel Agents and Strategies Under Evaluation for Advanced Gastroesophageal Cancers — Dr Klempner (1:44:23)

CME information and select publications

Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics:

• AKT inhibitors for PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (0:00)
• Radioligand-directed therapy for PSMA-positive metastatic hormone-sensitive prostate cancer (8:18)
• Radiation therapy in combination with enzalutamide for high-risk localized prostate cancer (13:14)

CME information and select publications